Hologic (HOLX)
NASDAQ:HOLX
Top Page
Hologic
(NASDAQ:HOLX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$82.00
▲(7.88% Upside)
Action:ReiteratedDate:04/06/26
The score is driven primarily by strong cash flow and a stable balance sheet, partially offset by a sharp TTM revenue decline and margin compression. Technicals are mildly supportive with price holding above key moving averages, while valuation is less compelling at ~23x earnings with no dividend yield provided.
Positive Factors
Strong cash generation
Sustained near-$1B free cash flow and positive FCF growth support durable internal funding for R&D, capital expenditures, and potential deleveraging. High cash conversion (FCF ~88% of net income TTM) underpins long-term financial flexibility and resilience through cycles.
Negative Factors
Sharp revenue decline
A near‑25% TTM revenue decline is a durable concern: it erodes operating scale, pressures gross and operating margins, and limits reinvestment capacity. If top-line weakness persists, it will curtail long-term growth, pricing leverage, and the company’s ability to fund innovation organically.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Sustained near-$1B free cash flow and positive FCF growth support durable internal funding for R&D, capital expenditures, and potential deleveraging. High cash conversion (FCF ~88% of net income TTM) underpins long-term financial flexibility and resilience through cycles.
Read all positive factors
Hologic (HOLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.97B
Dividend YieldN/A
Average Volume (3M)6.29M
Price to Earnings (P/E)23.3
Beta (1Y)>-0.01
Revenue Growth1.74%
EPS Growth-25.29%
CountryUS
Employees7,063
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.04
Shares Outstanding223,244,900
10 Day Avg. Volume12,306,202
30 Day Avg. Volume6,293,303
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)3.02
Price to Sales (P/S)3.72
P/FCF Ratio16.60
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue4.20
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda17.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)4.48
Revenue Forecast (FY)$4.22B
Hologic Business Overview & Revenue Model
Company Description
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. I...
How the Company Makes Money
Hologic makes money primarily by selling medical devices/instruments and the related recurring consumables and services that go with them. A significant portion of revenue comes from Diagnostics, where Hologic sells molecular diagnostic testing pl...
Hologic Key Performance Indicators (KPIs)
Any
Revenue By Segment
Analyzes revenue from each business segment, providing insight into which areas are driving growth and contributing most to the company’s overall performance.
Analyzes revenue from each business segment, providing insight into which areas are driving growth and contributing most to the company’s overall performance.
Data provided by:
The Fly
The FlyHologic Earnings Call Summary
Earnings Call Date:Jul 30, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with strong financial performance and promising developments in the Breast Health and Diagnostics segments. Despite some challenges in specific markets and product lines, the company's strategic initiatives and successful product launches indicate a solid path toward growth.Positive Updates
Strong Financial Performance
Hologic delivered revenue and non-GAAP earnings per share that exceeded guidance, with total revenue for the third quarter at $1.024 billion, marking a slight growth of 0.4% and exceeding the high end of guidance by $14 million.
Negative Updates
Breast Health Revenue Decline
Despite improvements, Breast Health revenue declined 5.8% or 10.8% organically, attributed to a tough comparison from the previous year.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Financial Performance
Hologic delivered revenue and non-GAAP earnings per share that exceeded guidance, with total revenue for the third quarter at $1.024 billion, marking a slight growth of 0.4% and exceeding the high end of guidance by $14 million.
Read all positive updates
Company Guidance
During Hologic's Third Quarter Fiscal 2025 earnings call, the company reported exceeding its guidance with total revenue reaching $1.024 billion, a 0.4% increase year-over-year, surpassing the high end of their guidance by $14 million. The Diagnostics division achieved revenue of $448.9 million, growing 2.9% organically when excluding COVID-related sales, while the Breast Health business, despite a 5.8% decline, showed sequential improvement. The Surgical segment saw a 6.3% increase in revenue, and the Skeletal business grew 62.1% following a resumption in DEXA model shipments. Non-GAAP earnings per share rose by 1.9% to $1.08, slightly above guidance, with a strong operating margin of over 30%. The company anticipates mid-single-digit organic revenue growth into fiscal 2026, bolstered by strengthening in the Breast Health sector and strategic innovations like the Genius AI Detection PRO.Hologic Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.13B | 4.10B | 4.03B | 4.03B | 4.86B | 5.63B |
| Gross Profit | 2.18B | 2.50B | 2.23B | 2.07B | 3.00B | 3.80B |
| EBITDA | 1.01B | 1.02B | 1.30B | 1.11B | 2.11B | 2.86B |
| Net Income | 543.90M | 565.70M | 789.50M | 456.00M | 1.30B | 1.87B |
Balance Sheet | ||||||
| Total Assets | 9.18B | 9.01B | 9.16B | 9.14B | 9.07B | 8.92B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 2.20B | 2.33B | 2.72B | 2.34B | 1.17B |
| Total Debt | 2.52B | 2.63B | 2.66B | 2.90B | 2.92B | 3.14B |
| Total Liabilities | 3.94B | 3.97B | 4.03B | 4.12B | 4.20B | 4.70B |
| Stockholders Equity | 5.25B | 5.05B | 5.13B | 5.02B | 4.88B | 4.22B |
Cash Flow | ||||||
| Free Cash Flow | 999.60M | 920.10M | 1.15B | 901.00M | 2.00B | 2.15B |
| Operating Cash Flow | 1.10B | 1.06B | 1.29B | 1.05B | 2.13B | 2.33B |
| Investing Cash Flow | -472.80M | -482.70M | -781.00M | -152.10M | -206.30M | -1.33B |
| Financing Cash Flow | -250.90M | -777.20M | -1.11B | -483.20M | -756.00M | -529.80M |
Hologic Technical Analysis
Positive
76.01
Price Trends
75.29
Positive
75.02
Positive
71.28
Positive
Market Momentum
0.13
Negative
68.74
Neutral
73.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOLX, the sentiment is Positive. The current price of 76.01 is above the 20-day moving average (MA) of 75.47, above the 50-day MA of 75.29, and above the 200-day MA of 71.28, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 68.74 is Neutral, neither overbought nor oversold. The STOCH value of 73.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOLX.
Hologic Risk Analysis
Hologic disclosed 13 risk factors in its most recent earnings report. Hologic reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hologic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $33.21B | 22.47 | 24.81% | 0.92% | 9.36% | 29.56% | |
75 Outperform | $161.56B | 70.78 | 16.39% | ― | 22.18% | 21.37% | |
72 Outperform | $18.62B | 40.29 | 16.68% | 0.32% | 4.90% | -0.26% | |
68 Neutral | $44.27B | 28.46 | 6.93% | 2.13% | 8.23% | -2.04% | |
67 Neutral | $16.97B | 23.34 | 11.01% | ― | 1.74% | -25.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $8.93B | -10.24 | -13.78% | 2.75% | -21.20% | -325.40% |
* Healthcare Sector Average
HOLX
Hologic
76.01
18.16
31.39%
BAX
Baxter International
17.30
-10.16
-37.01%
BDX
Becton Dickinson
155.46
0.53
0.34%
ISRG
Intuitive Surgical
454.94
-38.66
-7.83%
RMD
Resmed
227.98
15.89
7.49%
WST
West Pharmaceutical Services
258.54
48.58
23.14%
Hologic Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A Transactions
Hologic CEO Retirement Announced Amid Private Equity Buyout
Positive
Apr 6, 2026
On April 6, 2026, Hologic announced that long-time Chairman, President and CEO Steve MacMillan, who joined the company in 2013 and became chairman in 2015, will retire immediately after the closing of its go-private acquisition by Blackstone and T...
M&A TransactionsShareholder Meetings
Hologic Shareholders Approve Blackstone and TPG Buyout Deal
Positive
Feb 6, 2026
On February 5, 2026, Hologic held a special meeting of stockholders to vote on the proposed acquisition of the company by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC. Stockholders representing about 80% of outstanding shares...
Business Operations and StrategyFinancial DisclosuresLegal ProceedingsM&A Transactions
Hologic Faces Merger-Related Stockholder Suits, Issues Disclosures
Negative
Jan 26, 2026
Hologic, Inc. has disclosed that stockholder litigation and demand letters have been filed in January 2026 challenging disclosures in its proxy materials for the planned merger with Hopper Parent Inc., alleging material omissions and seeking to bl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.